Original news and analysis on international IP policy
A new report launched in time for this week's AIDS conference in South Africa analyzes factors relating to access to HIV/AIDS treatments over the past 15 years. The analysis includes a look at government policies used during that time, the contribution of generic and research-based industries, and the importance of voluntary licensing.
Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.
Gilead is the US company whose use of patents to charge $1000 per pill for a hepatitis C medicine in the United States helped make high drug prices a developed country household issue and fodder for elected officials seeking change. Now the company has come under further fire after being found to have moved some US$10 billion overseas to avoid US taxes - even after having received US taxpayer support for its activities - which it orchestrated by moving its patent rights overseas. A new report detailing the company's tax dodge includes a proposal for a way to clamp down on this type of patent activity.
A new book and website examine the impact of intellectual property rights on access to new essential medicines and call for measures that were used to reduce prices of patented HIV medicines to be applied in the case of essential medicines.
Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are flawed, writes Steven Tepp.
Today the Medicines Patent Pool announced the signing of nine new sub-licensing agreements for the generic manufacturing of key HIV and hepatitis C treatments.
What do global innovators make of India’s new National Intellectual Property Rights Policy? A recent discussion on “India’s National IPR Strategy: A View from Global Innovators” in Washington DC attempted to assess the opportunities and challenges ahead from the perspective of American companies.
The Netherlands’ Presidency of the European Council proved to be far from quiet in relation to pharmaceutical affairs. June 17 was the concluding Health Ministers Council (EPSCO) that signed off the most strongly-worded conclusions Brussels observers can recall. The meeting signaled the end of an overall successful and impactful Presidency in the highly sensitive field of medicines. The past semester has been eventful to say the least.
A resolution on access to medicines proposed by a number of developing countries was adopted today by the United Nations Human Rights Council, as well as a resolution on enhancing capacity-building in public health. This marks yet another United Nations fora in which developing countries seek to raise the issue of access to medicines, particularly with regard to high prices.
World Intellectual Property Organization members attending this week’s patent law committee meeting agreed on a work programme, reflecting divergent views on patents and health, exceptions and limitations, and patent quality.
This week in the World Intellectual Property Organization patent law committee, the African Group submitted an updated proposal for a work programme on patents and health that would help developing countries tailor patent law to their circumstances.
A top Ecuadoran official said today at the United Nations in Geneva that WikiLeaks founder Julian Assange’s health is deteriorating after four years confined in the Ecuadoran embassy in London, while the United Kingdom and Sweden are ignoring the findings of the UN Working Group on Arbitrary Detention which called for Assange’s release. The Ecuadoran Minister of Foreign Affairs also said Ecuador will carry on issuing compulsory licences for medicines as it sees fit, underlining the increasing role of intellectual property and the greater privatisation of knowledge.